Clinical Trial Contact Request

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Please complete the form below to be contacted by our Clinical Trial Information Service
 (1024)
By submitting this form, you accept our Terms & Conditions and grant permission for us to contact you. We will not sell or share your information (Privacy Policy). Please do not submit another person’s name or email without his or her consent.